Delivery of neoadjuvant chemoradiation for patients with stage II and III rectal cancer is suboptimal

Abstract

The use of guideline‐recommended therapy of neoadjuvant chemoradiation and surgery for patients with rectal cancer has increased over the past decade, but nevertheless only 55% of patients received such treatment. Being of nonwhite race or Hispanic ethnicity, lacking private insurance, and living in an area with low aggregate educational levels were associated with a lower probability of receiving trimodality therapy.